Login to Your Account



Sleep Maintenance Data Less Convincing

Vanda Improves Sleep Onset in Phase III Insomnia Trial

By Trista Morrison


Friday, June 27, 2008
Shares of Vanda Pharmaceuticals Inc. rose and then fell on Thursday as investors tried to digest top-line data from the company's Phase III trial of tasimelteon (VEC-162) in chronic insomnia. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription